33 related articles for article (PubMed ID: 38462470)
1. A case of Empty Sella syndrome with adrenal insufficiency masked by prednisolone after administration of immune checkpoint inhibitors.
Iwamoto Y; Tatsumi F; Ohnishi M; Katakura Y; Kimura T; Shimoda M; Nakanishi S; Mune T; Kaneto H
Medicine (Baltimore); 2024 Mar; 103(10):e37204. PubMed ID: 38457550
[TBL] [Abstract][Full Text] [Related]
2. Autopsy case: Pathological complete response in an advanced lung cancer patient with severe immune related adverse events and COVID-19.
Moriya R; Kamihata N; Niwa Y; Kako H; Takahashi H; Kimura Y; Shigeyasu Y; Tsukamoto T; Hashimoto N; Imaizumi K
Respir Investig; 2024 May; 62(3):438-441. PubMed ID: 38518583
[TBL] [Abstract][Full Text] [Related]
3. Severe upper gastrointestinal disorders in pembrolizumab-treated non-small cell lung cancer patient.
Onuki T; Morita E; Sakamoto N; Nagai Y; Sata M; Hagiwara K
Respirol Case Rep; 2018 Aug; 6(6):e00334. PubMed ID: 30065841
[TBL] [Abstract][Full Text] [Related]
4. Refractory pembrolizumab immunotherapy-related colitis requiring biological therapy in an inactive HBcAb carrier.
Rasheed N; Anand R; Maddox M; Reyes C
BMJ Case Rep; 2023 Sep; 16(9):. PubMed ID: 37751983
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors-Associated Generalized Lipodystrophy: Reconstructive Challenges of an Emerging and Distinct Form of Lipodystrophy.
Kreutz-Rodrigues L; Cherukuri S; Rames JD; Chen A; Meira Pazelli A; Mardini S; Gibreel W
J Craniofac Surg; 2024 Jun; ():. PubMed ID: 38869298
[TBL] [Abstract][Full Text] [Related]
6. Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review.
Barron CC; Stefanova I; Cha Y; Elsolh K; Zereshkian A; Gaafour N; McWhirter E
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37536939
[TBL] [Abstract][Full Text] [Related]
7. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
[TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
10. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
11. Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Yamamoto T; Ito T; Hase T; Ishigami M; Mizuno K; Yamamoto K; Imai N; Ishizu Y; Honda T; Shibata H; Hatta T; Yogo N; Yasuda S; Toyoda H; Abe T; Kawashima H; Hashimoto N; Fujishiro M
Cancer Invest; 2022 Feb; 40(2):189-198. PubMed ID: 34658277
[TBL] [Abstract][Full Text] [Related]
12. [A case of immune-related gastroesophagitis with laryngopharyngitis caused by immune checkpoint inhibitors in nonsmall cell lung cancer].
Oka Y; Hamano Y; Nakamura R; Mabuchi K; Ochi M; Yamaguchi Y; Okawara H; Okawara A; Kakinoki N; Kamoshida T
Nihon Shokakibyo Gakkai Zasshi; 2024; 121(3):221-229. PubMed ID: 38462470
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor-related chronic pneumonitis: a case report and literature review.
Yuan-Di Wang ; Yuan S; Wen C; Ji Z; Xiang B; Wang B; Zhang Z
Immunotherapy; 2023 Oct; 15(14):1117-1123. PubMed ID: 37431609
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]